Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan

被引:0
|
作者
Siegel, JA
Zimmerman, BE
Kodimer, K
Dell, MA
Simon, WE
机构
[1] Nucl Phys Enterprises, Wellington, FL 33414 USA
[2] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA
[3] Cardinal Hlth Nucl Pharm Serv, Woodland Hills, CA USA
[4] Capintec Inc, Ramsey, NJ USA
[5] Sun Nucl Corp, Melbourne, FL USA
关键词
Y-90; measurement; dose calibrator; ibritumomab tiuxetan;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
This investigation examined the accuracy of dose calibrator activity measurement of the beta-emitting radiopharmaceutical Y-90-ibritumomab tiuxetan. Methods: Five different facilities independently measured Y-90 in a 10-mL syringe geometry with 30 dose calibrator models from 3 different manufacturers. The activities ranged from 81.4 MBq (2.2 mCi) to 1,406 MBq (38 mCi) over the volume range of 3-9 mL. Results: The mean dial settings for Y-90 measurement were 375, 51 x 10, and 897 x 100 for Atomlab, CRC, and Mark V dose calibrators, respectively. The maximum volume dependence was 0.28%/mL. Conclusion: This study demonstrated that when measuring all volumes of Y-90-ibritumomab tiuxetan activity prescriptions, only a single dial setting for a given manufacturer's dose calibrator is required for accurate measurements. Volume corrections are not necessary. For best accuracy, an individually determined dial value should be used.
引用
收藏
页码:450 / 454
页数:5
相关论文
共 50 条
  • [41] Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan or 131I-Tositumomab
    Baechler, Sebastien
    Hobbs, Robert F.
    Jacene, Heather A.
    Bochud, Francois O.
    Wahl, Richard L.
    Sgouros, George
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (12) : 1878 - 1884
  • [42] Consolidation of chemotherapy response in mantle cell lymphoma (MCL) patients with 90Y-ibritumomab tiuxetan (90Y-Zevalin) radioimmunotherapy (RIT).
    Jurczak, W
    Giza, A
    Krochmalczyk, D
    Wegrzyn, J
    Hubalewska-Dydejczyk, A
    Sowa-Staszczak, A
    Knopinska-Posluszny, W
    Zdziarska, B
    Kyrcz-Krzemien, S
    Boguradzki, P
    Poplawska, L
    Skotnicki, A
    BLOOD, 2005, 106 (11) : 690A - 690A
  • [43] 90Y-ibritumomab tiuxetan:: Rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma
    Grillo-López, AJ
    SEMINARS IN ONCOLOGY, 2005, 32 (01) : S44 - S49
  • [44] Initial experience with rituximab and 90Y-ibritumomab tiuxetan for the treatment of mature B-cell lymphoma.
    Al-Shemmari, Salem H.
    Al-Mohannadi, Shihab M.
    Khan, Haider A.
    Sajnani, Kamlesh P.
    BLOOD, 2006, 108 (11) : 266B - 267B
  • [45] Single center experience of 90Y-Ibritumomab tiuxetan in the older population with non-hodgkin lymphoma.
    Agrawal, Vaibhav
    Castillo, Jose Isaac
    Raup, Kelly
    Girton, Treanna
    Collins, Scott R.
    Brady, James O.
    Khan, Sharif S.
    Vadakara, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] 90Y-ibritumomab tiuxetan therapy of follicular non-Hodgkin's lymphoma: the experience in our hospital
    Ramal Leiva, D.
    Sabate-Llobera, A.
    Mercadal Vilchez, S.
    Garcia Munoz, N.
    Roca Engronyat, M.
    Mora Salvado, J.
    Martin-Comin, J.
    Gonzalez-Barca, E.
    Ricart Brulles, Y.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S429 - S429
  • [48] Validation of autoradiochromatography as safe alternative technique to beta counting for determination of radiochemical purity of 90Y-ibritumomab tiuxetan
    Di Franco, M.
    Scotognella, T.
    Martinengo, E.
    Angusti, T.
    Rabbia, C.
    Podio, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S507 - S507
  • [49] RADIOIMMUNOTHERAPY CASES REGISTRY: RECURRENT OR REFRACTORY NON-HODGKIN LYMPHOMA TREATED WITH 90Y-IBRITUMOMAB TIUXETAN
    Gomez-Codina, J.
    Giraldo, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 232 - 232
  • [50] Report of a European consensus workshop to develop recommendations for the optimal use of 90Y-ibritumomab tiuxetan (Zevaline®) in lymphoma
    Hagenbeek, A
    Lewington, V
    ANNALS OF ONCOLOGY, 2005, 16 (05) : 786 - 792